Our technologies are suitable for a number of applications in drug discovery including ADCs, Binders, GPCRs, MHC-I/Peptide Complexes as well as bispecifics and multispecific constructs.
Antibody-drug conjugates (ADCs) are a recognized, potent class of targeted therapeutics and receptor-mediated internalization is absolutely essential for ADC functionality. To develop a potent ADC, antibodies need to be selective for a given target and also trigger high internalization rates. AbCheck’s microfluidics platform is designed towards both key requirements for potent ADCs, target selectivity and efficient internalization and our internalization assay ensures reliable detection of exclusively intracellular signals from target expressing cells.
AbCheck’s microfluidics platform can be used for both detection of binders and functional sorting. Our binding assays are designed for the detection of not only regular binders to recombinant purified antigens rare mAb clones, but also enable detection of binders with high specificity against homologous targets such as MHC-I/peptide complexes mutated variants of receptors or orthologues, as well as binders to targets integrated into cell membranes and VLPs.
AbCheck has developed an assay to directly discover agonistic antibodies based on proprietary sensor cells. These engineered cell lines changing fluorescence upon induction with active molecules (e.g. agonistic mAbs). Potential targets include receptors like (G protein-coupled receptors) GPCRs, receptor tyrosine kinases (RTKs) and ion channels. Our approach has been successfully tested with GPCRs of multiple receptor families.
Classical antibody therapies are restricted to cell surface proteins, but nature uses MHC-I/peptide complexes as „windows“ to monitor the appearance of unusual intracellular proteins. Peptide-specific binding of such complexes use intracellular proteins as tumor specific targets for antibodies or antibody-based binding units. Discovery of antibodies binding a specific peptide in the content of MHC-peptide complexes is extremely challenging. AbCheck has developed a process for the discovery of antibodies for peptide-specific targeting of MHC-I complexes, aiming to broaden the target space for tumor therapy. We have generated a transgenic rabbit model carrying the human MHC-I gene and our proprietary microfluidics/dual-staining-based narrow-specificity sorting offers an easy and efficient way of generating highly specific high-affinity antibodies to MHC-I/peptide complexes in this model.